Rznomics
Latest round
- Series C
Last raised
- Jun 2022
Total raised
- $48M
Investors
- 14
About Rznomics
Founded in 2017 and based in Seongnam, South Korea, Rznomics Inc. is a company that develops new drugs for ribonucleic acid or RNA-based gene therapy through a trans-splicing ribozyme with a mechanism for removing disease-causing target RNA being replaced with therapeutic RNA. The company develops pharmaceuticals for liver cancer, glioblastoma, Alzheimer's disease, and hereditary retinitis pigmentosa.
Who invested in Rznomics
14 investors across 4 rounds
See all investors in Rznomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rznomics
Who invested in Rznomics?
Rznomics has 14 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rznomics raised?
Rznomics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Rznomics last raise money?
Rznomics's most recent round on record is a Series C, in Jun 2022.
What does Rznomics do?
Founded in 2017 and based in Seongnam, South Korea, Rznomics Inc.
Where is Rznomics headquartered?
Rznomics is headquartered in Yongin-si, South Korea.
Which VCs invest in companies like Rznomics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Rznomics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Rznomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.